Compare Stocks

Date Range: 

 Intercept PharmaceuticalsChimerixZIOPHARM OncologyVBI VaccinesVeru
SymbolNASDAQ:ICPTNASDAQ:CMRXNASDAQ:ZIOPNASDAQ:VBIVNASDAQ:VERU
Price Information
Current Price$18.21$8.15$3.10$2.73$7.48
52 Week RangeHoldBuyHoldBuyBuy
MarketRank™
Overall Score2.21.71.31.51.4
Analysis Score4.14.53.23.63.5
Community Score3.12.42.43.22.9
Dividend Score0.00.00.00.00.0
Ownership Score3.31.70.80.80.0
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$42.83$18.80$5.60$7.00$19.20
% Upside from Price Target135.18% upside130.67% upside80.65% upside156.41% upside156.68% upside
Trade Information
Market Cap$562.10 million$690.55 million$641.31 million$671.08 million$531.43 million
Beta1.851.882.282.140.71
Average Volume1,151,8941,015,7972,496,0765,974,3803,602,063
Sales & Book Value
Annual Revenue$252 million$12.52 million$150,000.00$2.22 million$42.59 million
Price / Sales2.4056.124,447.57312.5912.63
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.57 per share$1.79 per share$0.52 per share$0.50 per share$0.43 per share
Price / Book11.604.555.965.4617.40
Profitability
Net Income$-344,680,000.00$-112,580,000.00$-117,800,000.00$-54,810,000.00$-18,970,000.00
EPS($10.89)($0.86)($0.34)($0.46)($0.11)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-106.64%-321.31%N/A-2,837.73%-44.55%
Return on Equity (ROE)-1,973.10%-36.57%-48.49%-36.69%-23.72%
Return on Assets (ROA)-48.51%-33.53%-43.53%-28.29%-13.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.10%N/A
Current Ratio3.44%12.18%10.12%9.06%1.83%
Quick Ratio3.44%12.18%10.12%8.95%1.38%
Ownership Information
Institutional Ownership Percentage85.77%45.41%48.00%52.13%23.32%
Insider Ownership Percentage23.70%9.00%2.30%10.50%26.10%
Miscellaneous
Employees49854103127339
Shares Outstanding33.16 million86.21 million215.21 million254.20 million71.91 million
Next Earnings Date8/9/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)7/30/2021 (Estimated)5/12/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
What Makes ING (ING) a Good Fit for "Trend Investing" - NasdaqWhat Makes ING (ING) a Good Fit for "Trend Investing" - Nasdaq
nasdaq.com - May 11 at 1:32 PM
My Plea to Investors Right Now - NasdaqMy Plea to Investors Right Now - Nasdaq
nasdaq.com - May 10 at 8:57 PM
Builders FirstSource (BLDR) Buys Johns Lumber, Boosts Presence - NasdaqBuilders FirstSource (BLDR) Buys John's Lumber, Boosts Presence - Nasdaq
nasdaq.com - May 10 at 3:55 PM
Why Veru (VERU) Might Surprise This Earnings Season - Yahoo FinanceWhy Veru (VERU) Might Surprise This Earnings Season - Yahoo Finance
finance.yahoo.com - May 10 at 3:55 PM
Why Veru (VERU) Might Surprise This Earnings SeasonWhy Veru (VERU) Might Surprise This Earnings Season
finance.yahoo.com - May 10 at 3:55 PM
Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -11.76% This Week? - InvestorsObserverWhere Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -11.76% This Week? - InvestorsObserver
investorsobserver.com - May 7 at 5:39 PM
Veru (NASDAQ:VERU) Trading 8.6% Higher Veru (NASDAQ:VERU) Trading 8.6% Higher
americanbankingnews.com - May 7 at 12:56 PM
Veru Inc. (NASDAQ:VERU) Forecasted to Earn FY2022 Earnings of $0.00 Per ShareVeru Inc. (NASDAQ:VERU) Forecasted to Earn FY2022 Earnings of $0.00 Per Share
americanbankingnews.com - May 7 at 11:35 AM
Veru (NASDAQ:VERU) Stock Price Down 11.9%Veru (NASDAQ:VERU) Stock Price Down 11.9%
americanbankingnews.com - May 6 at 1:54 PM
Premarket Mover: Veru Inc (VERU) Up 14.56% - InvestorsObserverPremarket Mover: Veru Inc (VERU) Up 14.56% - InvestorsObserver
investorsobserver.com - May 6 at 8:53 AM
$14.36 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter$14.36 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter
americanbankingnews.com - May 6 at 4:48 AM
Clinical News: MDMA and Therapy Significantly Benefits PTSD Patients and More - BioSpaceClinical News: MDMA and Therapy Significantly Benefits PTSD Patients and More - BioSpace
biospace.com - May 5 at 5:52 PM
Veru (VERU) Stock Rises After Enobosarm Shows Clinical Benefits in Phase 2 Trial - InvestorsObserverVeru (VERU) Stock Rises After Enobosarm Shows Clinical Benefits in Phase 2 Trial - InvestorsObserver
investorsobserver.com - May 5 at 5:52 PM
Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo FinanceVeru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
finance.yahoo.com - May 5 at 5:52 PM
Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - May 5 at 5:52 PM
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021 - Yahoo FinanceVeru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021 - Yahoo Finance
finance.yahoo.com - May 5 at 12:51 PM
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
finance.yahoo.com - May 5 at 12:51 PM
Verus Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer PatientsVeru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
finance.yahoo.com - May 5 at 12:51 PM
Veru (NASDAQ:VERU) Shares Gap Up to $8.70Veru (NASDAQ:VERU) Shares Gap Up to $8.70
americanbankingnews.com - May 5 at 12:05 PM
Veru (VERU) to Release Quarterly Earnings on WednesdayVeru (VERU) to Release Quarterly Earnings on Wednesday
americanbankingnews.com - May 5 at 6:58 AM
Will Top-Line Growth Buoy Motorolas (MSI) Q1 Earnings? - NasdaqWill Top-Line Growth Buoy Motorola's (MSI) Q1 Earnings? - Nasdaq
nasdaq.com - May 4 at 1:20 PM
Vitum að staðan er flókinVitum að staðan er flókin
mbl.is - May 4 at 8:19 AM
-$0.03 Earnings Per Share Expected for Veru Inc. (NASDAQ:VERU) This Quarter-$0.03 Earnings Per Share Expected for Veru Inc. (NASDAQ:VERU) This Quarter
americanbankingnews.com - May 4 at 2:12 AM
Veru Inc. (NASDAQ:VERU)’s Share Price Fell Recently, Although No Trouble Is On The HorizonVeru Inc. (NASDAQ:VERU)’s Share Price Fell Recently, Although No Trouble Is On The Horizon
stocksregister.com - May 3 at 2:54 PM
Veru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th - Yahoo FinanceVeru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th - Yahoo Finance
finance.yahoo.com - April 28 at 11:43 PM
DateCompanyBrokerageAction
5/10/2021Intercept PharmaceuticalsOppenheimerLower Price Target
5/7/2021Intercept PharmaceuticalsThe Goldman Sachs GroupLower Price Target
5/7/2021Intercept PharmaceuticalsRaymond JamesLower Price Target
5/7/2021Intercept PharmaceuticalsBMO Capital MarketsLower Price Target
5/7/2021Intercept PharmaceuticalsCantor FitzgeraldLower Price Target
5/6/2021Intercept PharmaceuticalsStifel NicolausLower Price Target
3/18/2021Intercept PharmaceuticalsHC WainwrightUpgrade
3/8/2021Intercept PharmaceuticalsWedbushLower Price Target
3/8/2021Intercept PharmaceuticalsNeedham & Company LLCLower Price Target
3/1/2021Intercept PharmaceuticalsB. RileyLower Price Target
3/1/2021Intercept PharmaceuticalsChardan CapitalLower Price Target
1/15/2021Intercept PharmaceuticalsBank of AmericaDowngrade
12/21/2020Intercept PharmaceuticalsJefferies Financial GroupDowngrade
11/11/2020Intercept PharmaceuticalsCanaccord GenuityBoost Price Target
11/10/2020Intercept PharmaceuticalsRoyal Bank of CanadaLower Price Target
5/5/2021ChimerixMaxim GroupInitiated Coverage
4/12/2021ChimerixJonestradingReiterated Rating
5/9/2019ChimerixCowenReiterated Rating
3/6/2019ChimerixCitigroupLower Price Target
6/21/2020ZIOPHARM OncologyLaidlawReiterated Rating
12/14/2020VeruBrookline Capital ManagementBoost Price Target
3/20/2019VeruCIBCInitiated Coverage
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.